AI-enhanced electrocardiograms can now screen for left-heart conditions, specifically asymptomatic aortic stenosis and grade-3 diastolic dysfunction [1, 2].
This shift toward AI-driven screening matters because it provides a low-cost, widely available tool to identify early-stage valvular disease before symptoms appear. By catching these conditions early, providers can improve patient prognoses and reduce the reliance on expensive medical imaging [1, 5].
Development of this technology is advancing through several regulatory and legal milestones. The European Patent Office granted a fundamental patent for the assessment of diastolic function using AI-ECG on April 24, 2024 [2]. Additionally, the FDA granted a breakthrough device designation on Oct. 28, 2024, for an AI algorithm designed to detect grade-3 diastolic dysfunction [4].
Technical precision is driven by massive datasets. The EchoNext AI-enhanced ECG model was trained using more than 1.2 million ECG-echocardiogram pairs [5]. This scale allows the AI to identify subtle patterns in heart electricity that correlate with physical structural issues in the heart valves.
Industry collaboration is also expanding to bring these tools to clinical settings. On June 25, 2026, AISAP and Cardiology Consultants of Philadelphia (CCP) announced a strategic partnership to combat heart failure and valvular disease through an advanced AI cardiac platform [3].
"Partnering with AISAP allows us to be at the forefront of the AI revolution in medicine," Dr. Mark Victor said [3].
These efforts are being coordinated across several hubs, including the Mayo Clinic in Rochester, Minnesota, HeartSciences headquarters in Southlake, Texas, and clinical activities in Philadelphia [1, 2, 3].
“AI-enhanced ECGs can screen for left-heart conditions, specifically asymptomatic aortic stenosis.”
The integration of AI into standard ECGs represents a transition from reactive to proactive cardiology. By converting a common, inexpensive test into a sophisticated screening tool for diastolic dysfunction and aortic stenosis, the medical community can identify high-risk patients who would typically remain undetected until a major cardiac event occurs.
